An interventional study of Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy and Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy in Stones, Kidney and Ureteric Injury, sponsored by Ain Shams University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by Ain Shams University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Kidney Calculi by Ain Shams University — 6 open to participants now, 7 under way, none of them phase 3. Kidney Calculi · Ain Shams University.
Among the 14 studies in Kidney Calculi by Ain Shams University, this one is the 7th largest by planned enrollment, is one of 7 that started in 2025, is one of 13 with no phase, and was the 4th registered.
510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.
Browse Kidney Calculi studies →6 of the 14 studies in Kidney Calculi by Ain Shams University are open now, in 1 country. Recruiting first, the newest first:
Ain Shams University · Sites in Egypt
Ages 18–60
Ain Shams University · Sites in Egypt
Ages 18–71
Ain Shams University · Sites in Egypt
Ages 18+
Ain Shams University · Sites in Egypt
Ages 16+ · Healthy volunteers
Ain Shams University · Sites in Egypt
Ages 18–60
By country, each count listing its studies:
Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2021; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 129 is above the median of 86 across 392 interventional studies indexed under Kidney Calculi.
Median enrollment 128 across the 14 interventional studies. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ain Shams University is the lead sponsor of 1,958 studies on the registry; 432 are open to participants now.
Of its 35 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
1 of the studies in Kidney Calculi by Ain Shams University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07516535Ain Shams UniversityDISS vs FANS in Suction-Assisted RIRS for Medium-Sized Renal Stones | 2027-04-30 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Kidney Calculi by Ain Shams University, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
in this study we are going to evaluate the efficacy of intra-ureteric aminophylline instillation in facilitating ureteric access sheath placement prior to flexible ureteroscopy in reducing ureteric injury rates.
Urolithiasis (kidney and ureteral stones) is a common urologic condition with increasing prevalence. Flexible ureteroscopy (FURS) is a minimally invasive technique widely used for upper ureteric and renal stones. Aminophylline, a methylxanthine derivative, has been shown to relax smooth muscles and was previously used intravesically to facilitate rigid ureteroscopy with reduced complications. This study aims to assess whether intra-ureteric aminophylline instillation improves the ease of ureteral access sheath (UAS) placement during FURS and reduces ureteric injuries.
patients will be divided into 3 groups:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
a ureteric catheter 6 Fr will be used for instillation of normal saline supplemented with aminophylline 250 mg/10 mL at three points (Pelvi-ureteric junction, upper sacroiliac joint level and proximal to uretero-vesical junction by 5 cm) then wait for 5 minutes
Drug: Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy
traditional ureteral dilators will be used. We will start by ureteral dilator 6 fr and gradually increase the size up to 12 Fr
Device: Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy
Aminophylline will be instilled as in group (A) then followed by traditional ureteral dilatation as in group (B)
Drug: Usage of Aminophylline prior to ureteric dilatation in Flexible uretroscopy · Device: Sequential teflon dilator usage prior to ureteric access sheath placement in flexible uretroscopy · Other: Aminophylline instillation and Ureteral dilators together
Intraureteric aminophylline installation prior to ureteric dilatation
Also known as: Intraureteric Aminophylline instillation prior to access sheath insertion
traditional ureteral dilators will be used. We will start by ureteral dilator 6 fr and gradually increase the size up to 12 Fr
Also known as: ureteric teflon dilators prior to access sheath insertion
Aminophylline will be instilled as in group (A) then followed by traditional ureteral dilatation as in group (B) prior to placing the ureteric access sheath
Also known as: combination of aminophylline instillation and ureteric teflon dilators prior to access sheath insertion
The successful placement of ureteric access sheath
we will assess the successful placement of ureteric access sheath in patients (that the access sheath is passed on the guide wire till the pelviureteric junction portion of the ureter after the usage of intraureteric aminophylline or teflon dilators or the usage of both.
Time frame: intraoperative application of the access sheath
successful stone clearance
the stone free rate following intervention
Time frame: 3 weeks postoperative follow up with urinary tract multislice CT
Plan to share: No
Started Mar 2025 (actual). Primary completion is estimated for Jan 2026, 10 months after the start.
Of 183 non-industry interventional studies with no phase under Kidney Calculi, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 54. This study's planned 10 months is below that.
Counting every sponsor, half of 199 studies reached it within 26 months; a quarter within 12 and three quarters within 51.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.